



GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer

January 2, 2025

Experienced Diagnostics Executive with a Proven Record of Driving Business Growth to Lead Product & Technology, Operations, Medical Affairs, Innovation and More

New Executive Leadership Positions Company for Growth and Scale

STAMFORD, Conn.--(BUSINESS WIRE)--Jan. 2, 2025-- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced the appointment of Bryan Dechairo as Chief Operating Officer, effective immediately. In the newly created role, Bryan will report to Katherine Stueland, CEO and President, and will serve on the company's executive leadership team.

As Chief Operating Officer, Bryan will oversee Product & Technology, Operations, Medical Affairs, Innovation, and the Program Management teams at GeneDx. He will be pivotal in driving operational excellence as the company enters the next phase of commercial growth.

"Bryan's extensive clinical, technical and operational experience and proven ability to lead scalable transformations will play a pivotal role in helping us execute our strategic vision and accelerate the adoption of genomic insights across healthcare," said Stueland. "As we embark on the next phase of our growth and scale, I am confident Bryan's leadership will be critical in helping us deliver impactful genomic insights and improve health outcomes for an ever-growing number of patients and families."

Bryan brings over 30 years of experience in exploratory and commercial diagnostic businesses, driving the development of revenue-generating clinical innovations that enhance patient outcomes. He most recently served as President and CEO of Sherlock Biosciences, where he successfully transformed the company from a research-stage start-up into a commercial operation. Bryan has also held executive leadership roles at prominent diagnostic and pharmaceutical companies, including Pfizer, Myriad Genetics, Assurex, Medco Health and others. Bryan holds a PhD in Human Genetics from the University College of London and a BA in Integrative Biology from the University of California Berkeley.

"GeneDx has built a market-leading position in pediatric genetics and has an incredible opportunity to pave the way for the genomics revolution in healthcare today," said Dechairo. "With world-class products, advanced AI and the most dynamic minds in the industry, I'm looking forward to supercharging operational excellence to accelerate profitable growth."

About GeneDx:

GeneDx (Nasdaq: WGS) delivers personalized and actionable health insights to inform diagnosis, direct treatment, and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its industry-leading exome and genome testing and interpretation services, fueled by the world's largest, rare disease data sets. For more information, please visit www.genedx.com and connect with us on [LinkedIn](#), [Facebook](#), and [Instagram](#).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250102377634/en/): <https://www.businesswire.com/news/home/20250102377634/en/>

Press@genedx.com

Investors@genedx.com

Source: GeneDx